Catalent Company profile
Catalent Pharma is the US number one health products and solutions provider. The company specialises in biologics, pre-formulation and formulation and runs its own optoform technology. Catalent Pharma prides itself on 1,300 patents and 7,000 products currently in market. The company's operations stretch across Asia Pacific, Europe, Latin America, and North America, covering more than 100 global markets.
Since 2014, Catalent stocks have been traded on the New York Stock Exchange (NYSE) under the CTLT ticker. The company is featured in the Top 50 pharma and Top 50 biotech companies lists. As of May 2018, the Catalent market cap reached 5.348B.
Browse the latest Catalent share price data and tap into the pharma industry at Capital.com.
Latest shares articles
ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
14:15, 16 October 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:41, 11 September 2024
Stocks struggle for direction as US jobs data fails to give assurance
Traders struggle to find a direction as the latest US jobs data gives a mixed picture heading into the FOMC September meeting.
13:32, 6 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
09:13, 29 August 2024
Ratings and Reviews
Ratings and Reviews
